Active	Status	Sponsor type	Region	Phase	Filter
3 Active 9 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bogenschutz, Michael P
NCT05452772: 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder	Recruiting	2	66	US	Psilocybin, Active Experimental Group, Niacin, Active Comparator Group	Johns Hopkins University, University of Alabama at Birmingham, New York University, Sheppard Pratt Health System, National Institute on Drug Abuse (NIDA)	Tobacco Use Disorder	05/25	12/25
NCT06349083: Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD	Not yet recruiting	2	200	US	Psilocybin, Inactive Placebo, Supportive therapy sessions	NYU Langone Health, National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Alcohol Use Disorder	01/29	01/29
NCT06796062: Psilocybin for Opioid Use Disorder (OUD)	Not yet recruiting	2	480	US	Psilocybin	NYU Langone Health, National Institute on Drug Abuse (NIDA)	Opioid Use Disorder	03/29	09/29